Evidence map›Paper›PMID 36297679›Full record

ReviewPharmaceutics2022

Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications.

Zahra Rezaei, Dilara Yilmaz-Aykut, Fatima Mumtaza Tourk, Nicole Bassous, Margot Barroso-Zuppa, Asif Iqbal Shawl, Syed Salman Ashraf, Huseyin Avci, Shabir Hassan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 5 countries.

Zahra RezaeiDivision of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.
Dilara Yilmaz-AykutDivision of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.ORCID 0000-0002-2287-2585
Fatima Mumtaza TourkDivision of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.
Nicole BassousDivision of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.
Margot Barroso-ZuppaDivision of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.ORCID 0000-0001-6211-3367
Asif Iqbal ShawlDepartment of Biology, College of Arts and Sciences, Main Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates.
Syed Salman AshrafDepartment of Biology, College of Arts and Sciences, Main Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates.ORCID 0000-0003-4961-5527
Huseyin AvciDepartment of Metallurgical and Materials Engineering, Eskisehir Osmangazi University, 26040 Eskisehir, Turkey.ORCID 0000-0002-2475-1963
Shabir HassanDivision of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.ORCID 0000-0002-5822-9508
Brigham and Women's Hospital · USKhalifa University of Science and Technology · AEEskişehir Osmangazi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-targeted persistent immune activation or suppression by different drug delivery platforms can cause adverse and chronic physiological effects including cancer and arthritis. Therefore, non-toxic materials that do not trigger an immunogenic response during delivery are crucial for safe and effective in vivo treatment. Hydrogels are excellent candidates that can be engineered to control immune responses by modulating biomolecule release/adsorption, improving regeneration of lymphoid tissues, and enhancing function during antigen presentation. This review discusses the aspects of hydrogel-based systems used as drug delivery platforms for various diseases. A detailed investigation on different immunomodulation strategies for various delivery options and deliberate upon the outlook of such drug delivery platforms are conducted.

Indexed as

biomaterialsforeign body responsehydrogelsimmune modulationtissue engineering

Identifiers

PMID36297679
PMCPMC9610165
OpenAlexW4307264720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.